MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clinimag.2025.110570

Медицинская библиотека · Clinical imaging · 2025

The role of PSMA PET/CT in distinguishing malignant from benign solitary bone lesions in prostate cancer patients.

Shah Nadia, Sedeh Ashkan Eighaei, Deffler Caitlin, Ng Thomas S C, Mercaldo Nathaniel, Gao Xin, Mahmood Umar, Heidari Pedram, Esfahani Shadi A

СтатьяПеревод в очереди

Аннотация

PURPOSE: This study evaluates the ability of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) to distinguish between benign and malignant solitary bone lesions (SBLs) in prostate cancer (PCa) patients in correlation with standard imaging and clinical features.

METHODS

18F-piflufolastat and 68Ga-gozetotide PSMA PET/CT imaging reports of 1480 PCa patients from September 2021 to February 2023 were retrospectively reviewed. SBLs were classified as benign, malignant, or indeterminate based on imaging reports. Indeterminate SBLs were followed up over six months for reclassification. Comparative analyses, including Wilcoxon rank sum and chi-squared tests, assessed differences in standardized uptake values on PET, prostate-specific antigen (PSA) levels, and lesion locations.

RESULTS

208 of 1480 (14 %) PSMA PET/CT scans reported an SBL. 106/208 (51 %) SBLs were malignant, 56/208 (27 %) benign, and 46/208 (22 %) indeterminate. Compared to benign lesions, malignant SBLs had a significantly higher SUVmax [5.20 (2.86-11.13) vs. 2.21 (1.6-2.84); p < 0.001] and SUVmax/liver SUVmean [0.9 (0.51-2.31) vs. 0.44 (0.32-0.58); p < 0.001], although serum PSA levels were not significantly different. Malignant SBLs were most reported in pelvis (37/106, 35 %), while most benign SBLs were in ribs (31/56, 55 %). Presence or absence of non-osseous metastasis, and radiopharmaceutical type were not associated with significant differences in PSA, SUVmax, or the common locations of malignant or benign SBLs. Indeterminate SBLs were reclassified as benign in 20/46 (48 %) patients, most commonly in the ribs (19/46, 41 %).

CONCLUSION

Location, SUVmax, and SUVmax/liver SUVmean of SBL on PSMA PET/CT may help differentiate benign from malignant etiologies while considering other imaging and clinical features.

Для цитирования: Shah Nadia, Sedeh Ashkan Eighaei, Deffler Caitlin, Ng Thomas S C, Mercaldo Nathaniel, Gao Xin, Mahmood Umar, Heidari Pedram, Esfahani Shadi A. The role of PSMA PET/CT in distinguishing malignant from benign solitary bone lesions in prostate cancer patients.. Clinical imaging. 2025. DOI: 10.1016/j.clinimag.2025.110570.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.